SCHEDULE: Heights Capital Management and CVI Investments Disclose 5.7% Stake in BriaCell Therapeutics
Beneficial Ownership Report
Heights Capital Management, acting as investment manager for CVI Investments, Inc., has disclosed a 5.7% beneficial ownership stake in BriaCell Therapeutics Corp., holding 1,000,000 common shares.
Summary
- CVI Investments, Inc. and Heights Capital Management, Inc. jointly reported beneficial ownership of 1,000,000 common shares of BriaCell Therapeutics Corp.
- This ownership represents 5.7% of the outstanding common shares of BriaCell Therapeutics Corp.
- Heights Capital Management, Inc. serves as the investment manager for CVI Investments, Inc. and exercises shared voting and dispositive power over these shares.
- The filing date for the event triggering this disclosure was July 15, 2025.
- BriaCell Therapeutics Corp. had 17,551,092 common shares outstanding as of the completion of a recent offering, excluding shares underlying pre-funded and other warrants.
Sentiment
Score: 6
Explanation: The filing is a standard beneficial ownership disclosure, indicating a significant institutional stake in BriaCell Therapeutics Corp. by CVI Investments, Inc. and Heights Capital Management, Inc. While not providing operational or financial performance details, the disclosure of a 5.7% stake by an investment firm can be viewed as a neutral to slightly positive signal of institutional interest.
Positives
- A significant institutional investor, CVI Investments, Inc., through its investment manager Heights Capital Management, Inc., has disclosed a 5.7% stake in BriaCell Therapeutics Corp., indicating a notable investment position.
Negatives
- No specific negative financial or operational information about BriaCell Therapeutics Corp. is disclosed in this beneficial ownership filing.
Risks
- No specific risks related to BriaCell Therapeutics Corp.'s operations or financial health are detailed in this beneficial ownership statement.
- The reporting persons certify that the securities were not acquired for the purpose of changing or influencing control of the issuer.
Future Outlook
No forward-looking statements or guidance regarding BriaCell Therapeutics Corp.'s future performance or strategic direction are provided in this beneficial ownership filing.
Management Comments
- No direct quotes or paraphrased statements from BriaCell Therapeutics Corp. management are included in this filing.
- Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc., certified the accuracy of the statement.
Industry Context
This filing indicates a significant institutional investment in BriaCell Therapeutics Corp., a company operating in the biotechnology sector, specifically in cancer therapeutics. Such disclosures are common for institutional investors crossing ownership thresholds.
Comparison to Industry Standards
- This Schedule 13G filing primarily concerns beneficial ownership disclosure and does not provide information for direct comparison to industry-specific operational or financial benchmarks of comparable companies or projects.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | No changes in directors, officers, or key personnel of BriaCell Therapeutics Corp. are reported in this filing. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | No changes in BriaCell Therapeutics Corp.'s bylaws, committees, policies, or procedures are disclosed. | NA | NA |
| Internal Governance Document | A Limited Power of Attorney dated July 16, 2015, grants Heights Capital Management, Inc. authority to enter into transactions on behalf of CVI Investments, Inc. | July 16, 2015 | Formalizes the investment management relationship and transaction authority between CVI Investments, Inc. and Heights Capital Management, Inc. |
Legal Proceedings
- No litigation or regulatory matters concerning BriaCell Therapeutics Corp. are disclosed in this filing.
Related Party Transactions
- The filing details the relationship between CVI Investments, Inc. and Heights Capital Management, Inc., where Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and exercises shared voting and dispositive power over the reported shares.
Stakeholder Impact
- Shareholders: Existing shareholders will note a significant institutional investor holding a 5.7% stake, which could be perceived as a vote of confidence.
- Management: BriaCell Therapeutics Corp. management is now aware of this significant institutional ownership.
Next Steps
- No specific future actions, events, or milestones for BriaCell Therapeutics Corp. are mentioned in this beneficial ownership filing.
Key Dates
| Date | Description |
|---|---|
| July 16, 2015 | Limited Power of Attorney given by CVI Investments, Inc. to Heights Capital Management, Inc. |
| July 16, 2015 | Discretionary Investment Management Agreement between CVI Investments, Inc. and Heights Capital Management, Inc. |
| July 15, 2025 | Date of event which requires filing of this statement (beneficial ownership threshold crossed). |
| July 16, 2025 | Date of Prospectus (Registration No. 333-288562) filing by BriaCell Therapeutics Corp., indicating 17,551,092 shares outstanding. |
| July 22, 2025 | Date of signing of the Schedule 13G and Joint Filing Agreement. |
Recommendation
holdThis Schedule 13G filing primarily serves as a disclosure of beneficial ownership, indicating that CVI Investments, Inc., managed by Heights Capital Management, Inc., holds a 5.7% stake in BriaCell Therapeutics Corp. While the presence of a significant institutional investor can be viewed as a positive signal of confidence, the filing itself does not provide sufficient financial performance data, strategic updates, or operational details of BriaCell Therapeutics Corp. to warrant a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, pending further analysis of the company's fundamental performance and future prospects.
Keywords
BriaCell Therapeutics, CVI Investments, Heights Capital Management, Schedule 13G, beneficial ownership, common shares, investment, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.